DJIA 18,054.46 -81.26 -0.45%
NASDAQ 4,979.04 -3.77 -0.08%
S&P 500 2,093.27 -7.77 -0.37%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)

2.76 -0.11 (-3.83%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

VVUS $2.76 -3.83%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.86
Previous Close $2.87
Daily Range $2.74 - $2.89
52-Week Range $2.41 - $6.40
Market Cap $286.7M
P/E Ratio -3.59
Dividend (Yield) $0.00 (0.0%)
Volume 402,952
Average Daily Volume 2,105,262
Current FY EPS -$1.26

Sector

Healthcare

Industry

Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary

Why Orexigen Therapeutics, Inc. Stock Exploded Higher

Orexigen Therapeutics looks like it has the first game-changing obesity drug on its hands. Here's what you need to know.

Orexigen Soars: Good News Is Heart Data, Bad News Is Data May Be Compromised

Cardiovascular Safety Surprise: Wait, Then Buy Orexigen

Orexigen Weight-Loss Pill Shows Surprise Heart-Safety Benefit

Vivus - Flat Qsymia Scripts Point To Needed Shift

Vivus Sinking With Dwindling Qsymia Market Share

Orexigen's Q4 Results Disappoint, But Contrave Is Gaining Market Share

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst B

Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blog

Orexigen Therapeutics, Inc. Gives the Skinny on Its Drug Launch

Fourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.

VIVUS Q4 Loss Wider than Expected, Qsymia Disappoints - Analyst Blog

See More VVUS News...

VVUS's Top Competitors

VVUS $2.76 (-3.83%)
Current stock: VVUS
JNJ $101.26 (-1.23%)
Current stock: JNJ
NVS $97.96 (-1.00%)
Current stock: NVS
RHHBY $33.09 (0.90%)
Current stock: RHHBY